MetaCap

iTonic Holdings Ltd Class A (ITOC)

NASDAQ: ITOCHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

1.59+0.09 (+6.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ITOC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$11.63M
EPS (TTM)
-$4.22
52-week range
1.40 – 18.40
Day range
1.45 – 1.81
Volume / Avg
160.43K / 42.84K
Beta
—

52-week range

$1.40$18.40

ITOC stock today

Shares of iTonic (ITOC) finished higher on Nov 20 at $1.59, a gain of 6.00% or $0.09 per share, versus the S&P 500's 3.70% decline. Volume was 3.7x the average at 160.43K shares, a sign of unusually heavy trading. Shares are 91.4% below their 52-week high of $18.40, set on Jun 8, 2026 and 13.6% above the 52-week low of $1.40, near the bottom of the past year's range.

ITOC is down 76.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.0%. iTonic has posted a net loss over the last twelve months (EPS of -$4.22), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About iTonic

Company profile

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.

Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
CEO
Mr. Jianfei Zhang
Headquarters
Beijing
Employees
7
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, iTonic generated $523,031 in revenue, up 16.7% from fiscal 2024. iTonic reported a net loss of $5.1 million, compared with a loss of $660,588 a year earlier. Gross margin was 62.6% (down from 85.0%) and operating margin -991.7%.

iTonic annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue$523.03K$448.20K$628.59K$679.78K
Growth+16.70%-28.70%-7.53%—
Net income$-5.10M$-660.59K$-241.22K$83.98K
EPS (diluted)$-0.318$-0.052$-0.02$0.007

ITOC news

All ITOC news

iTonic peers

Health Care sector
ITOC peer companies
CompanyPrice% ChgMarket capCompare
IRIXIRIDEX Corporation0.4449-4.59%$7.92Mvs ITOC
NDRAENDRA Life Sciences Inc.3.58-3.38%$5.36Mvs ITOC
NUWENuwellis Inc.3.41-10.50%$1.84Mvs ITOC
NXLNexalin Technology Inc.1.38-2.13%$1.71Mvs ITOC
VBIOValion Bio Inc.0.4806-10.98%$1.04Mvs ITOC
QTIQT Imaging Holdings Inc.1.92+2.67%$28.21Mvs ITOC
ECORelectroCore Inc.4.42-8.87%$40.78Mvs ITOC
POCIPrecision Optics Corporation Inc.4.12+1.41%$45.30Mvs ITOC

Indexes, lists and sector

iTonic stock FAQ

What is iTonic's stock price today?

ITOC last traded at $1.59 as of Nov 20, 4:00 PM EST, up 6.00% on the day. Prices are delayed at least 15 minutes.

Does iTonic pay a dividend?

No. iTonic does not currently pay a regular cash dividend.

Who is iTonic's CEO?

Mr. Jianfei Zhang is the chief executive officer of iTonic Holdings Ltd Class A, which has about 7 employees.

Has ITOC ever split its stock?

Yes. The most recent ITOC stock split was a 1-for-16 split on Oct 6, 2026.

What is the ITOC 52-week high?

The 52-week high for ITOC is $18.40 and the 52-week low is $1.40. The stock is currently 91.4% below its high.

Compare ITOC